Skip to main content

Table 1 Clinical and biochemical characteristics of heFH and control probands

From: Current causes of death in familial hypercholesterolemia

  heFH Cases Controls P
N 83 83  
Age (years) 54.3 (10.7) 54.5 (10.5) 0.884
Women, N (%) 45 (54.2) 44 (53.0) 0.876
Current smokers, N (%) 11 (13.3) 22 (26.5) 0.098
BMI (Kg/m2)a 25.8 (3.94) 26.3 (4.17) 0.479
Systolic blood pressure (mmHg) 123.1 (12.7) 123.3 (14.0) 0.956
Diastolic blood pressure (mmHg) 74.6 (8.97) 75.3 (9.97) 0.628
Hypertension, N (%) 24 (28.9) 16 (19.8) 0.172
Type 2 diabetes mellitus, N (%) 7 (8.4) 7 (8.4) 1.000
Cardiovascular disease, N (%) 7 (8.4) 2 (2.4) 0.087
Total cholesterol (mg/dL) 363 (412–306) 220 (198–252)  < 0.001
LDL cholesterol (mg/dL)b 283 (222–339) 130 (105–154)  < 0.001
HDL cholesterol (mg/dL)c 56.2 (13.4) 62.0 (24.2) 0.079
Triglycerides (mg/dL) 114 (52.3) 141 (154) 0.209
Glucose (mg/dL) 89.5 (18.8) 91.3 (20.1) 0.626
Statin treatment, N (%) 83 (100) 19 (22.9)  < 0.001
Onset age of statin treatment (years) 32.8 (9.43) 51.3 (8.84)  < 0.001
  1. Data are summarized as mean (SD) or N (percentage)
  2. aBMI denotes body mass index
  3. bLDL, low-density lipoprotein
  4. cHDL, high-density lipoprotein